Sunho Biologics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	0.04	17.53	1.85	3.22
Revenue	0.04	17.53	1.85	3.22
Revenue Growth (YoY)	-99.78%	847.78%	-42.48%	-
Gross Profit	0.04	17.53	1.85	3.22
Selling, General & Admin	30.28	40.7	5.56	5.8
Research & Development	71.12	43.04	53.17	64.03
Other Operating Expenses	-	0.07	1.26	-
Operating Expenses	101.39	83.81	59.99	69.83
Operating Income	-101.36	-66.28	-58.14	-66.62
Interest Expense	-0.92	-0.69	-5.07	-4.17
Interest & Investment Income	9.45	3.47	0.02	0.01
Currency Exchange Gain (Loss)	3.84	-8.29	0.03	-0
Other Non Operating Income (Expenses)	9.02	-60.91	11.18	0.01
EBT Excluding Unusual Items	-79.97	-132.7	-51.99	-70.78
Gain (Loss) on Sale of Investments	-	-	-	0.15
Pretax Income	-79.97	-132.7	-51.99	-70.63
Net Income	-79.97	-132.7	-51.99	-70.63
Net Income to Common	-79.97	-132.7	-51.99	-70.63
Shares Outstanding (Basic)	128	93	91	91
Shares Outstanding (Diluted)	128	93	91	91
Shares Change (YoY)	38.04%	2.07%	-	-
EPS (Basic)	-0.62	-1.43	-0.57	-0.78
EPS (Diluted)	-0.62	-1.43	-0.57	-0.78
Free Cash Flow	-148.39	-41.68	-36.03	-58.17
Free Cash Flow Per Share	-1.16	-0.45	-0.40	-0.64
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-266723.68%	-378.00%	-3142.54%	-2071.39%
Profit Margin	-210434.21%	-756.82%	-2810.16%	-2196.27%
Free Cash Flow Margin	-390505.26%	-237.73%	-1947.30%	-1808.71%
EBITDA	-94.41	-59.88	-51.54	-64.21
D&A For EBITDA	6.95	6.4	6.6	2.4
EBIT	-101.36	-66.28	-58.14	-66.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.